Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma

OBJECTIVE To identify biomarkers associated with the effectiveness of ipilimumab plus nivolumab against advanced metastatic renal cell carcinoma. METHODS We retrospectively analyzed the data of 75 patients treated with ipilimumab plus nivolumab at seven hospitals between August 2018 and April 2021. Prognostic biomarkers were assessed prior to initiating treatment with ipilimumab plus nivolumab. Median overall survival and progression-free survival were examined using the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify predictors of disease progression. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors most important for predicting disease progression were determined using classification and regression tree analysis. RESULTS Median overall survival and progression-free survival were longer in the intermediate IMDC risk group than in the poor IMDC risk group (overall: not reached vs. 18.3 months; progression-free: not reached vs. 13.5 months). The multivariate analysis identified poor IMDC risk as a risk factor for disease progression (hazard ratio 2.61, 95% confidence interval: 1.05-6.51). Based on the results of the classification and regression tree analysis, the cohort was divided into non-anemia, anemia + neutro-Low, and anemia + neutro-High groups. Median overall survival and progression-free survival were longer in the non-anemia and anemia + neutro-Low groups than in the anemia + neutro-High group (overall: not reached vs. 29.3 months vs. 4.3 months: progression-free: not reached vs. 29.0 months vs. 3.9 months). CONCLUSION Hemoglobin and neutrophil levels may represent crucial biomarkers for predicting the effectiveness of ipilimumab plus nivolumab therapy in patients with renal cell carcinoma.

[1]  Wei Huang,et al.  The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review , 2022, Frontiers in Surgery.

[2]  Guangcheng Luo,et al.  A meta-analysis of the platelet-lymphocyte ratio: A notable prognostic factor in renal cell carcinoma , 2022, The International journal of biological markers.

[3]  C. Porta,et al.  Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib , 2022, Therapeutic advances in medical oncology.

[4]  Xiuqiong Chen,et al.  Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis , 2021, Frontiers in Oncology.

[5]  Chun Wang,et al.  Prognostic Value of Pretreatment Prognostic Nutritional Index in Patients With Renal Cell Carcinoma: A Meta-Analysis , 2021, Frontiers in Oncology.

[6]  Yuan Wu,et al.  Prognostic Significance of Modified Advanced Lung Cancer Inflammation Index in Patients With Renal Cell Carcinoma Undergoing Laparoscopic Nephrectomy: A Multi-Institutional, Propensity Score Matching Cohort Study , 2021, Frontiers in Nutrition.

[7]  J. Grob,et al.  Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. , 2021, European journal of cancer.

[8]  C. Liu,et al.  Preoperative anaemia and thrombocytosis predict adverse prognosis in non‐metastatic renal cell carcinoma with tumour thrombus , 2021, BMC Urology.

[9]  S. Buti,et al.  Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis , 2021, Therapeutic advances in urology.

[10]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[11]  C. Porta,et al.  Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial , 2020, ESMO Open.

[12]  Yushen Wu,et al.  Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis , 2020, Cancer Cell International.

[13]  K. Miyazono,et al.  Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis , 2020, Nature Cell Biology.

[14]  E. Ozbek,et al.  Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma , 2020, International Urology and Nephrology.

[15]  N. Nishiyama,et al.  The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study , 2019, BMC Urology.

[16]  C. Ohyama,et al.  C‐reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma , 2019, International journal of urology : official journal of the Japanese Urological Association.

[17]  Qingshan Wang,et al.  The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer. , 2019, Journal of gastrointestinal oncology.

[18]  Lingyun Wu,et al.  Tumor-Associated Neutrophils in Cancer: Going Pro , 2019, Cancers.

[19]  A. Mantovani,et al.  Cancer Inflammation and Cytokines. , 2018, Cold Spring Harbor perspectives in biology.

[20]  T. Guzzo,et al.  Prognostic Significance of Preoperative Anemia in Patients Undergoing Surgery for Renal Cell Carcinoma: A Meta-analysis. , 2017, Anticancer research.

[21]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[22]  P. Prorok,et al.  Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. , 2011, Journal of the National Cancer Institute.

[23]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[24]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.